CClinicalTrials.gg
Not yet recruitingNCT05720208Updated Feb 9, 2023

Spinal Cord Innovation in Pediatrics (SCiP) to Treat SensoriMotor Function in Children Cerebral Palsy: Protocol for a Randomized Controlled Trial

A Phase 2 interventional study of SCiP in Cerebral Palsy, sponsored by SpineX Inc.. Not yet recruiting. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2023-02-09.

Sponsored by SpineX Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 1 month ago, but the record still lists the study as not yet recruiting.
Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
2 Years to 18 Years
Sex
All
01

Study summary

Cerebral palsy affects up to 4 children in 1000 live births, making it the most common motor disorder in children. It impairs the child's ability to move voluntarily and maintain balance and posture, and resultsing in a wide range of other functional disorders during early development that persist and frequently worsen with age including spasticity and often multiple abnormal sensationsensory modalities. Current standard of care treatments focus on symptom management and do not mitigate the progression of many of these underlying neurological impairments. The goal of this trial is to conduct a prospective multicenter, double-blinded, sham-controlled, crossover, randomized control trial to demonstrate the safety and efficacy of noninvasive spinal cord stimulation (using SCiPTM device, SpineX Inc.) in conjunction with activity-based neurorehabilitation therapy (ABNT) to improve voluntary sensorimotor function in children with cerebral palsy. 44 children participants (aged 2-18 years) diagnosed with CP classified as Gross Motor Function Classification Scale Levels I-V will be recruited and divided equally into two groups (G1 and G2). Both groups will receive identical ABNT 2 days/wk. G1 will initially receive sham stimulation, whereas G2 will receive therapeutic SCiPTM therapy for 8 weeks. After 8 weeks, G1 will cross over and receive therapeutic SCiPTM therapy for 8 weeks, whereas G2 will continue to receive SCiPTM therapy for another 8 weeks, for a total of 16 weeks. Primary and secondary outcome measures will include Gross Motor Function Measure-88 and Modified Ashworth Scale respectively.

02

Conditions studied

  • Cerebral Palsy

Browse trials for

03

In context

Cerebral Palsy

1,852 studies on the registry are indexed under Cerebral Palsy; 437 are open to participants now.

This study's planned enrollment of 60 is above the median of 34 across 1,368 interventional studies indexed under Cerebral Palsy.

Browse Cerebral Palsy studies →

Lead sponsor

SpineX Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Subject is ≥ 2 and ≤ 18 years old at the time of enrollment/consent.
  • Subject has a diagnosis of CP classified as Gross Motor Classification Scale Levels I-V.
  • Minimum score of 12 and Maximum score of 85 on the GMFM-88 total score scale.
  • Subject must have spastic CP hemiplegia or diplegia, quadriplegia.
  • Subject's medical condition is stable as determined by the investigator.
  • Subject has adequate social support network to be able to participate in training and assessment sessions for the duration of the study, at the discretion of the Investigator.
  • Subject is capable of performing simple cued motor tasks and can follow 2-3 step commands.
  • Subject can communicate an accurate yes or no answer to questions according to parents.

Exclusion criteria

Exclusion Criteria:

  • Subject has a concurrent neurological disease affecting the central nervous system.
  • Subject has implanted stimulator (e.g., epidural stimulator, vagus nerve stimulator, pacemaker, cochlear implant, etc.) or drug delivery device (e.g., baclofen pump)
  • Subject is dependent on an electro-magnetic medical implant (e.g., cardiac pacemaker or implanted drug pump), ventilation support, or another external device.
  • Subject has received botulinum toxin injection within 12 months preceding enrollment.
  • Subject is unable to participate in ABNT without orthosis.
  • Subject has limited life expectancy or co-morbid conditions, social/psychological problems, or cognitive impairments that, in the opinion of the investigator, will preclude them from participation and completion of study procedures or requirements.
  • Subject has a medical condition or complications related to the use of certain medications that may affect validity of the study as determined by the investigator.
  • Subject has a medical condition not listed above that may put the subject at risk as determined by the investigator.
  • Subject is participating in or plans to participate in another research study that may interfere with study endpoints.
  • Subject is known or suspected to be non-compliant; and/or subject is unable or unwilling to comply with study requirements.
  • Subject has cardiovascular or musculoskeletal disease or injury that would prevent full participation in physical therapy intervention
  • Subject has a history of uncontrolled seizures.
  • Subject has unhealed fracture or other musculoskeletal impairment that might interfere with upper or lower extremity rehabilitation or testing activities.
  • Subject has a history of orthopedic surgery in upper or lower extremities or neurosurgery that may be a confounding factor for interpretation of the results (such as tendon transfer, tendon or muscle lengthening for spasticity management, injection therapies to lower extremity muscles, percutaneous lengthening, spinal fusion etc.) in last 12 months.
  • Subject has a true leg length discrepancy greater than 2 cm.
  • Subject has established osteoporosis and taking medication for osteoporosis treatment.
  • Subject has undergone selective dorsal rhizotomy surgery.
  • Subject has hip or shoulder migration percentage > 30% on anteroposterior radiographic imaging.
  • Subject has less than 20 degrees in hip Range of Motion (ROM) in hip abduction.
  • Subject has unexplained presence of persistent complaints of pain of any kind.
  • Subject has fixed upper or lower extremity contractures of 20 degrees or more.
  • Subject has a fixed spinal scoliosis greater than 20 degrees.
  • Subject has severe cortico-visual impairment.
  • Subject has other ongoing, or who has discontinued less than 14 days prior to consent, physical and occupational therapies including but not limited to robotic therapy, gait training, aqua therapy, hippo therapy, intensive therapies, whole body vibration (WBV), stimulation therapies (e.g., E-Stimulation, Functional Electrical Stimulation (FES), Neuromuscular Electrical Stimulation (NMES)).
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Therapeutic Arm

    Device: SCiP

  • Sham comparator
    Sham Arm

    Device: SCiP

Interventions

  • DeviceSCiP

    Noninvasive Spinal Cord Neuromodulator

06

What researchers measure

Primary outcomes

  1. GMFM88

    Time frame: 8 weeks

Secondary outcomes

  1. Modified Ashworth Scale

    Time frame: 8 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05720208
Lead sponsor
SpineX Inc.
Responsible party
Sponsor
First posted
Feb 9, 2023
Start date
Sep 1, 2023 (estimated)
Primary completion
Sep 1, 2024 (estimated)
Completion
Sep 1, 2025 (estimated)
Last update
Feb 9, 2023

Study contacts

Parag Gad, PhD
Contact
info@spinex.co
408-203-5061

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion